Clinical Trials Sponsored by Ecogene 21

Total 1193 results

Celgene

Completed

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Poland, Ukraine, Hungary, Canada
Celgene

Completed

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Celgene

No longer available

Expanded Access for ACE-011

Myelodysplastic Syndrome

United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Psoriasis

United States, Canada
Celgene

Completed

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Colorectal Neoplasms

France
Celgene

Completed

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

United States
Celgene

Completed

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

Sarcoidosis, Pulmonary

United States, United Kingdom, Netherlands
Celgene

Completed

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

United States, Spain, Germany, France, Czechia, Australia, Sweden, United Kingdom, Ukraine, Poland
Celgene

Completed

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Melanoma | Sarcoma, Soft Tissue | Cancer | Fibrosarcoma | Neuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma | Neoplasm | Malignant Melanoma | Tumors | Histiocytoma | Dermatofibrosarcoma | Sarcoma, Ewing's | Neoplasia | Ewing's Sarcoma | Ewing's Tumor | Sarcomas, Epitheliod | Sarcoma, Spindle Cell | Clinical Oncology | Oncology,... and other conditions

United States, Canada, Spain, France, United Kingdom, Italy, Switzerland
Celgene

Completed

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Taiwan
Celgene

Completed

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Hematologic Malignancy | Malignant Lymphoma

United States, United Kingdom
Celgene

Terminated

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

Hemodialysis Graft Dysfunction

United States
Celgene

Completed

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

United States, Australia, Italy, Spain, France, Austria, Sweden, Czechia, United Kingdom
Celgene

Terminated

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

United States, Puerto Rico
Celgene

Completed

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Hormone Refractory Prostate Cancer

United States
Celgene

Completed

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function (RENAL)

Multiple Myeloma | Non-Hodgkin's Lymphoma | AML | Solid Tumors | MDS | Hodgkin's Disease

United States
Celgene

Terminated

A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). (RENEW)

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Spain, United Kingdom, Germany, France, Czechia, Israel, Italy, Poland, Portugal, Puerto Rico, Russian Federation
Celgene

Completed

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

Myelodysplastic Syndromes

Japan
Celgene

Terminated

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Carcinoma, Small Cell

United States, Canada
Celgene

Completed

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

Belgium, United Kingdom, Netherlands, Italy, Poland
Celgene

Completed

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Myelodysplastic Syndromes

United States, Germany
Celgene

Terminated

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Fibrosis | Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung Diseases, Interstitial | Interstitial Lung Disease

United States, Canada
Celgene

Completed

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies (GAH)

Myelodysplastic Syndromes | Multiple Myeloma | Leukemia Myeloid Acute | Leuklemia, Lymphocytic, Chronic

Spain
Celgene

Completed

A Safety Study of ABI-007 for In-Stent Restenosis

Coronary Artery Disease | Angina Pectoris

United States
Celgene

Completed

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma (OPTIMUM)

Multiple Myeloma

India, Philippines, France, Portugal, Poland, South Africa, Bulgaria, Croatia, Czechia, Germany, Hungary, Italy, Serbia, Slovakia, United Kingdom
Celgene

Approved for marketing

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma (PEXIUS)

Multiple Myeloma

United States, Canada
Celgene

Completed

Radiolabeled Study of CC-122 in Healthy Subjects

Healthy Volunteers

United States
Celgene

Completed

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
Celgene

Completed

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Healthy

United States
Celgene

Completed

CC-223 and Ketoconazole Drug-Drug Interaction Study

Healthy Volunteers
Celgene

Completed

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer

United States, Spain
Celgene

Completed

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Multiple Myeloma

China
Celgene

Completed

Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma

Multiple Myeloma

United Kingdom, France
Celgene

Completed

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

Japan
Celgene

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)

United States
Celgene

Completed

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Small Cell Lung Cancer

United States, United Kingdom, Australia, France, Canada, Netherlands, Poland, Spain, Switzerland, Italy, Denmark, Hungary, Germany, Bulgaria, Czechia, Austria, Belgium
Celgene

Completed

A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.

Advanced Solid Tumors

United States
Celgene

Terminated

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Pancreatic Neoplasms | Cholestasis

United States, Germany
Celgene

Completed

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

Myelodysplastic Syndromes

United States, France, Spain, Australia, Czechia, United Kingdom, Italy, Germany, Greece, Poland, Russian Federation, Bulgaria, Sweden, Netherlands, Hungary
Celgene

Completed

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

Small Cell Lung Cancer

United States, Netherlands, United Kingdom
Celgene

Completed

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Multiple Myeloma

Russian Federation
Celgene

Active, not recruiting

A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR

Multiple Myeloma

Turkey
Celgene

Completed

An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (OCEAN)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic
Celgene

Completed

Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response

Healthy Volunteer

United States
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
Celgene

Completed

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myelogenous Leukemia

United States, Canada
Celgene

Completed

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Breast Neoplasms | Pancreatic Neoplasms

United States

3

Subscribe